A new drug-eluting stent that does not live up to its promise

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

Original languageEnglish (US)
Pages (from-to)500-501
Number of pages2
JournalNature Reviews Cardiology
Volume6
Issue number8
DOIs
StatePublished - Jan 1 2009

Fingerprint

Drug-Eluting Stents
Tacrolimus
Stents
Coronary Artery Disease
Polymers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A new drug-eluting stent that does not live up to its promise. / Holmes, David.

In: Nature Reviews Cardiology, Vol. 6, No. 8, 01.01.2009, p. 500-501.

Research output: Contribution to journalArticle

@article{ff25eed121454d3c876a5e6d82eb279b,
title = "A new drug-eluting stent that does not live up to its promise",
abstract = "Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA{\circledR} stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.",
author = "David Holmes",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/nrcardio.2009.117",
language = "English (US)",
volume = "6",
pages = "500--501",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A new drug-eluting stent that does not live up to its promise

AU - Holmes, David

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

AB - Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

UR - http://www.scopus.com/inward/record.url?scp=70350445235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350445235&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2009.117

DO - 10.1038/nrcardio.2009.117

M3 - Article

C2 - 19633676

AN - SCOPUS:70350445235

VL - 6

SP - 500

EP - 501

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 8

ER -